Procore signs multi-year strategic collaboration agreement with AWS
NEW YORK - West Pharmaceutical (TADAWUL:2070) Services, Inc. (NYSE:WST) reported fourth-quarter earnings on Thursday that beat analyst expectations, but its stock tumbled 6.48% after the company’s 2025 guidance fell short of estimates.
The medical products manufacturer posted adjusted earnings per share of $1.82 for the fourth quarter, surpassing the analyst consensus of $1.72. Revenue came in at $748.8 million, exceeding expectations of $740.75 million and representing a 2.3% increase YoY. Organic net sales grew 3.3% compared to the same period last year.
Despite the quarterly beat, West Pharma’s outlook for 2025 disappointed investors. The company forecasts full-year 2025 revenue between $2.875 billion and $2.905 billion, below the $3.04 billion analysts were expecting. Adjusted EPS guidance of $6.00 to $6.20 also fell short of the $7.43 consensus estimate.
For the full year 2024, West Pharma reported net sales of $2.893 billion, a 1.9% decline YoY, while adjusted EPS fell 16.5% to $6.75.
The company expects organic net sales growth of 2% to 3% in 2025, factoring in a $75 million headwind from foreign currency exchange rates.
West Pharma also plans $275 million in capital spending for 2025 to support capacity expansions and investments in contract manufacturing facilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.